FTC backs generic pharma theories related to Parkinson’s drug

Several branded pharmaceutical companies have mischaracterised the launch of a generic alternative to their Parkinson’s Disease treatment as “free-riding”, the Federal Trade Commission has said while intervening in private litigation.